These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18558368)

  • 21. Novel antibodies as anticancer agents.
    Zafir-Lavie I; Michaeli Y; Reiter Y
    Oncogene; 2007 May; 26(25):3714-33. PubMed ID: 17530025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
    Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
    J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
    Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of two anti-tumour monoclonal antibody preparations.
    Price MR; Dennick RG; Fang CY; Hannant D; Embleton MJ; Gunn B; Baldwin RW
    Arch Geschwulstforsch; 1981; 51(4):302-9. PubMed ID: 6947720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine.
    Wagner S; Krepler C; Allwardt D; Latzka J; Strommer S; Scheiner O; Pehamberger H; Wiedermann U; Hafner C; Breiteneder H
    Clin Cancer Res; 2008 Dec; 14(24):8178-83. PubMed ID: 19088033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement-dependent cytotoxicity of anti-human osteogenic sarcoma monoclonal antibodies.
    Price MR; Pimm MV; Baldwin RW
    Br J Cancer; 1982 Oct; 46(4):601-10. PubMed ID: 6958308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy.
    Willemsen R; Chames P; Schooten E; Gratama JW; Debets R
    Cytometry A; 2008 Nov; 73(11):1093-9. PubMed ID: 18785268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New perspectives on complement mediated immunotherapy.
    Stasiłojć G; Österborg A; Blom AM; Okrój M
    Cancer Treat Rev; 2016 Apr; 45():68-75. PubMed ID: 26994325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development.
    Gancz D; Fishelson Z
    Mol Immunol; 2009 Sep; 46(14):2794-800. PubMed ID: 19501402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement-inhibiting effect of ovarian cancer antigen CA-125.
    Murdoch WJ; Van Kirk EA; Smedts AM
    Cancer Lett; 2006 May; 236(1):54-7. PubMed ID: 15985325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
    Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
    Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of a human IgM monoclonal antibody directed against HLA class II molecules: a potential agent in the treatment of haematological malignancies.
    Díaz B; Sanjuan I; Gambón F; Loureiro C; Magadán S; González-Fernández A
    Cancer Immunol Immunother; 2009 Mar; 58(3):351-60. PubMed ID: 18677479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.